tradingkey.logo

OmniAb Inc

OABI
1.380USD
-0.045-3.16%
Cierre 11/06, 16:00ETCotizaciones retrasadas 15 min
198.66MCap. mercado
PérdidaP/E TTM

Más Datos de OmniAb Inc Compañía

OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.

Información de OmniAb Inc

Símbolo de cotizaciónOABI
Nombre de la empresaOmniAb Inc
Fecha de salida a bolsaOct 09, 2020
Director ejecutivoMr. Matthew William (Matt) Foehr
Número de empleados114
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 09
Dirección5980 Horton Street
CiudadEMERYVILLE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94608
Teléfono15102507800
Sitio Webhttps://www.omniab.com/
Símbolo de cotizaciónOABI
Fecha de salida a bolsaOct 09, 2020
Director ejecutivoMr. Matthew William (Matt) Foehr

Ejecutivos de OmniAb Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
2.85M
+0.71%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Executive Vice President - Finance, Chief Financial Officer
Executive Vice President - Finance, Chief Financial Officer
223.83K
-12.04%
Dr. Carolyn R. Bertozzi, Ph.D.
Dr. Carolyn R. Bertozzi, Ph.D.
Independent Director
Independent Director
93.31K
+23.52%
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
71.67K
+22.86%
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Charles Stuart Berkman, J.D.
Mr. Charles Stuart Berkman, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Dr. Jennifer Cochran, Ph.D.
Dr. Jennifer Cochran, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven C. Crouse
Mr. Steven C. Crouse
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
2.85M
+0.71%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Executive Vice President - Finance, Chief Financial Officer
Executive Vice President - Finance, Chief Financial Officer
223.83K
-12.04%
Dr. Carolyn R. Bertozzi, Ph.D.
Dr. Carolyn R. Bertozzi, Ph.D.
Independent Director
Independent Director
93.31K
+23.52%
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
71.67K
+22.86%
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Service revenue
1.94M
49.68%
License and milestone revenue
1.24M
31.87%
xPloration revenue
608.00K
15.60%
Royalty revenue
111.00K
2.85%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Service revenue
1.94M
49.68%
License and milestone revenue
1.24M
31.87%
xPloration revenue
608.00K
15.60%
Royalty revenue
111.00K
2.85%

Estadísticas de accionistas

Actualizado: lun., 8 de sep
Actualizado: lun., 8 de sep
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Avista Capital Holdings, LP
10.99%
Whitefort Capital Management, LP
7.11%
Ash X LP
5.75%
BlackRock Institutional Trust Company, N.A.
4.40%
The Vanguard Group, Inc.
3.66%
Otro
68.09%
Accionistas
Accionistas
Proporción
Avista Capital Holdings, LP
10.99%
Whitefort Capital Management, LP
7.11%
Ash X LP
5.75%
BlackRock Institutional Trust Company, N.A.
4.40%
The Vanguard Group, Inc.
3.66%
Otro
68.09%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
16.23%
Hedge Fund
14.30%
Private Equity
12.89%
Investment Advisor/Hedge Fund
12.76%
Corporation
8.21%
Individual Investor
6.69%
Research Firm
1.01%
Pension Fund
0.14%
Venture Capital
0.11%
Otro
27.66%

Participación institucional

Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
349
70.66M
57.59%
-18.22M
2025Q2
348
92.68M
75.53%
-5.84M
2025Q1
359
87.33M
71.43%
-8.58M
2024Q4
365
89.85M
74.79%
-8.38M
2024Q3
394
90.25M
75.21%
-25.05M
2024Q2
389
89.07M
76.08%
-29.09M
2024Q1
378
93.24M
79.93%
-23.55M
2023Q4
374
92.06M
79.14%
-28.03M
2023Q3
352
92.71M
80.23%
-26.22M
2023Q2
337
91.30M
79.07%
-24.17M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Avista Capital Holdings, LP
15.82M
12.89%
--
--
Sep 30, 2024
Whitefort Capital Management, LP
10.24M
8.35%
+6.33M
+161.57%
Jun 30, 2025
Ash X LP
8.27M
6.74%
+2.86M
+52.77%
Aug 26, 2025
BlackRock Institutional Trust Company, N.A.
6.33M
5.16%
-122.32K
-1.89%
Jun 30, 2025
The Vanguard Group, Inc.
5.27M
4.29%
+89.01K
+1.72%
Jun 30, 2025
Foehr (Matthew W)
4.34M
3.53%
+540.54K
+14.24%
Aug 26, 2025
Dimensional Fund Advisors, L.P.
2.91M
2.37%
-217.95K
-6.96%
Jun 30, 2025
Higgins (John L)
2.85M
2.32%
+20.00K
+0.71%
Jun 17, 2025
Private Management Group, Inc.
2.56M
2.08%
+28.29K
+1.12%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.44M
1.99%
-21.63K
-0.88%
Jun 30, 2025
Ver más

ETFs relacionados

Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
iShares Micro-Cap ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Ver más
iShares Micro-Cap ETF
Proporción0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.02%
ProShares Ultra Nasdaq Biotechnology
Proporción0.02%
Invesco Nasdaq Biotechnology ETF
Proporción0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
Fidelity Enhanced Small Cap ETF
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
iShares Russell 2000 Value ETF
Proporción0.01%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI